-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Benzinga·08/07/2026 17:02:59
Listen to the news
Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.